Key points from article :
HepaRegenix secured €15 million to develop its liver regeneration drug HRX-215.
HRX-215 targets a protein (MKK4) that regulates liver regeneration.
Funding will support Phase 1b and international Phase 2a clinical trials of HRX-215.
HRX-215 aims to treat acute and chronic liver diseases, including liver tumors.
Preclinical studies showed promising results in reducing liver damage and tumor growth.
It may improve outcomes for liver transplant patients and other groups affected by liver failure.
Investors believe HRX-215 has the potential to significantly impact patients' lives.
